Shalini C Reshmi

List of Publications by Year
in descending order

32 papers	2,738 citations	567281 15 h-index	434195 31 g-index
32 all docs	32 docs citations	32 times ranked	4056 citing authors

#	Article	IF	Citations
1	Inherited and de novo variants extend the etiology of TAOK1-associated neurodevelopmental disorder. Journal of Physical Education and Sports Management, 2022, , mcs.a006180.	1.2	6
2	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	21.4	29
3	Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study.. Journal of Clinical Oncology, 2022, 40, 10023-10023.	1.6	1
4	Immune Reconstitution after Hematopoietic Stem Cell Transplantation in Immunodeficiencyâ€“Centromeric Instabilityâ€“Facial Anomalies Syndrome Type 1. Journal of Clinical Immunology, 2021, 41, 1089-1094.	3.8	2
5	5â€² <i>ALK</i> Amplification in Neuroblastoma: A Case Report. Case Reports in Oncology, 2021, 14, 585-591.	0.7	2
6	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
7	Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia. , 2021, , .		0
8	Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum. American Journal of Human Genetics, 2020, 107, 499-513.	6.2	48
9	Disease-associated mosaic variation in clinical exome sequencing: a two-year pediatric tertiary care experience. Journal of Physical Education and Sports Management, 2020, 6, a005231.	1.2	15
10	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. Blood, 2020, 136, 45-46.	1.4	6
11	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). Blood, 2020, 136, 44-45.	1.4	1
12	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. Blood, 2020, 136, 39-40.	1.4	2
13	Reclassification of Variants of Uncertain Significance in Children with Inherited Arrhythmia Syndromes is Predicted by Clinical Factors. Pediatric Cardiology, 2019, 40, 1679-1687.	1.3	24
14	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
15	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
16	Pericentromeric regions of homozygosity on the X chromosome: Another likely benign population variant. European Journal of Medical Genetics, 2018, 61, 416-420.	1.3	1
17	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Advances, 2018, 2, 529-533.	5.2	34
18	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Childrenâ€™s Oncology Group. Blood, 2018, 132, 815-824.	1.4	97

#	Article	IF	Citations
19	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	1.4	14
20	Genomic analysis of adult B-ALL identifies potential markers of shorter survival. Leukemia Research, 2017, 56, 44-51.	0.8	12
21	Targetable kinase gene fusions in high-risk B-ALL: a study from the Childrenâ€™s Oncology Group. Blood, 2017, 129, 3352-3361.	1.4	236
22	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature Communications, 2016, 7, 13331.	12.8	218
23	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 29, 186-200.	16.8	118
24	Variability in pathogenicity prediction programs: impact on clinical diagnostics. Molecular Genetics & Genomic Medicine, 2015, 3, 99-110.	1.2	44
25	Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival. Blood, 2015, 126, 1427-1427.	1.4	1
26	International Laboratory Comparison of Methodologies for Determining Minimal Residual Disease (MRD) in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blood, 2015, 126, 2612-2612.	1.4	2
27	Neurodevelopmental disorders among individuals with duplication of 4p13 to 4p12 containing a GABAA receptor subunit gene cluster. European Journal of Human Genetics, 2014, 22, 105-109.	2.8	20
28	Atypical breakpoint in a t(6;17) translocation case of acampomelic campomelic dysplasia. European Journal of Medical Genetics, 2014, 57, 315-318.	1.3	6
29	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
30	Functional Analysis of Kinase-Activating Fusions in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 786-786.	1.4	3
31	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€•or â€œBCR-ABL1-Likeâ€) Signature For Therapeutic Targeting and Clinical Intervention. Blood, 2013, 122, 826-826.	1.4	65
32	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. Blood, 2009, 114, 1580-1580.	1.4	7